Sculptra is an injection. Fat transfer is an operation. Sculptra is poly-L-lactic acid, or PLLA. These are tiny particles of a biodegradable synthetic material. They are injected into the deep skin, where they provoke the body into laying down new collagen. Fat transfer takes fat from somewhere else on your body by liposuction. The fat is processed, then re-injected into the face.
That one difference decides most of the rest. Sculptra is a clinic appointment with a needle, usually repeated across a course of sessions. Fat transfer needs a donor site, a surgical setting and sedation or anaesthesia. It also leaves two areas healing instead of one.
The hardest fact about fat transfer is that nobody can tell you how much of it you will keep. A systematic review and meta-analysis of 27 studies covering 1,011 patients put pooled facial fat retention at 47% (95% CI 41-53%). Individual studies ranged from 26% to 83% over 3 to 24 months of follow-up. The authors' own words were that "the exact percentage of facial fat grafts retained is currently unpredictable."
The two evidence bases are different shapes, and no one has ever compared them head to head. Sculptra went through the FDA's premarket approval route, PMA P030050. Randomised, evaluator-blinded trials sit behind its named indications, and the manufacturer ran them. Fat transfer is a surgical procedure rather than a device. So no FDA registration trial exists for it at all. Its literature is dominated by single-centre observational studies. No randomised trial has compared Sculptra with facial fat grafting, so nothing on this page can be read as one beating the other.
Freeze-dried PLLA powder mixed with sterile water before injection. Nothing looks fuller on the day.
Suctioned from a donor site, processed, then injected in small amounts.
In the trial behind the cheek approval people had a mean of 3.6 sessions, up to a maximum of four.
You heal in two places: where the fat was taken and where it was placed.
The particles are a scaffold. The volume comes from collagen laid down around them.
Ultrasound studies describe retention falling over roughly the first three to six months and then settling.
The original approval, dated 3 August 2004 in the FDA's database and 4 August in the approval summary, was for "restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with or receiving treatment for human immunodeficiency virus." Cosmetic indications came later: 2009 for nasolabial folds and other facial wrinkles, and 2023 for fine lines and wrinkles in the cheek region.
Surgery is not a device, so there is no premarket approval route and no regulatory dossier behind it.
Randomised, evaluator-blinded, no-treatment control, 149 people at 13 US sites, sponsored by Q-Med and Galderma Research and Development.
A separate review of 12 ultrasound-guided studies in 885 patients reported roughly 50% to 70% retention at one year.
Hyaluronidase dissolves hyaluronic acid fillers. It has no target in PLLA, and no reversal agent is approved for it.
Grafted fat cannot be dissolved either. It can be removed surgically, and it responds to your own weight changes.
In the cheek trial 20.6% had a treatment-related side effect; injection-site bruising was the most common at 11.3%, and one person in a hundred developed small nodules.
Firm painless lumps, fat necrosis and oil cysts are described weeks to months later; repeat grafting sessions and cryopreserved fat are named risk factors.
The signature Sculptra problem is delayed lumps. The label describes papules and nodules that are usually palpable rather than visible, appearing days to months after injection.
A review of 22 published articles found 58 complications in 38 patients, 32 of them severe or permanent, including hemiplegia in 11 people, vision loss in 7 and skin necrosis in 3. Most followed injection into the forehead or temple.
The 26% to 83% spread is not just biology. In the meta-analysis of 27 studies, retention differed significantly by how it was measured. Three-dimensional surface imaging, MRI, CT and subjective grading do not give the same answer. Retention was better in repeat grafting and in people treated for congenital deformities. Complications were recorded in 2.8%.
A second review makes the same point from the other direction. One review compared fat enriched with stromal vascular fraction against conventional grafting, across 18 studies and 893 patients. The enriched technique gained 17.20% retention (95% CI 11.26-23.15). But heterogeneity between studies was 98%, and that is the real headline. When studies disagree that much, pooling them barely means anything.
More than 94,000 autologous fat grafting procedures are performed in the United States each year. The same review that reports that number describes the procedure as limited by unpredictable fat cell survival. Over-correcting and planning a second session are standard practice for exactly this reason.
Sculptra has two panel-track pivotal trials with randomisation, evaluator blinding and a comparator arm - a collagen product in 2009, no treatment in 2023 - with pre-specified endpoints on wrinkle scales and follow-up to 25 and 24 months. That is unusually strong for an aesthetic injectable. The weaknesses are worth naming too: the pivotals were manufacturer-sponsored, the extension phases lost their control group, and the 2023 population was 96.6% female with 78.5% at Fitzpatrick skin types I to III.
Fat transfer has none of that structure and does not need it, because surgery is regulated differently. What it has instead is observational cohorts, retrospective series and narrative reviews, with the most-cited narrative review classed as the lowest level of evidence. It also has something Sculptra does not: the possibility of very long-lived correction for whatever fraction of the graft survives and grows a blood supply.
Neither treatment tightens loose skin: Both replace volume; lax skin stays lax.
Neither can be dissolved: Hyaluronic acid fillers such as Juvederm and Restylane can be broken down with hyaluronidase within minutes to hours. Sculptra and grafted fat cannot. In a review of 365 filler blindness cases published between 2018 and 2023, autologous fat accounted for 13.5% - and there is no enzyme that removes it.
Sudden change or loss of vision, or double vision
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or pale, then dusky, blotchy or mottled
Drooping on one side of the face, weakness in an arm or leg, or trouble speaking
These can mean filler or fat has entered an artery. Time matters in hours.
Swelling keeps growing after the first few days instead of settling
A lump appears and will not settle, or one appears weeks or months later
Redness is spreading outward from an injection site, or you develop a fever
Tenderness, redness or firmness appears weeks after treatment
One side starts to look hollow or uneven compared with the other